<DOC>
	<DOC>NCT01879475</DOC>
	<brief_summary>The effectiveness objective of this study is to evaluate whether 032-11 is non-inferior to Floseal as an adjunct to achieving haemostasis during surgical procedures involving cardiac and aortic thoracic surgery.</brief_summary>
	<brief_title>Safety and Performance of 032-11 Haemostat in Cardiac and Thoracic Aortic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>The patient must be equal or greater than 18 years old The patient must have elective or nonelective urgent cardiac surgery or thoracic aortic surgery The patient must have no childbearing potential or have a negative serum or urine pregnancy test within 7 days of the planned surgery or in the opinion of the Investigator performs adequate contraception The patient is willing and able to be contacted for the followup visit at 6 8 weeks The patient must provide written informed consent using a form that is reviewed and approved by the IEC The patient is currently enrolled in this or another investigational device or drug trial that has not completed the required follow up period. The patient has a known hypersensitivity to materials of bovine origin The patient does not wish to receive materials of bovine or shellfish origin for any reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>